Diamyd Medical AB (OSTO:DMYD B) Debt-to-Equity : 0.00 (As of May. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Debt-to-Equity?

Diamyd Medical AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2025 was kr0.00 Mil. Diamyd Medical AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2025 was kr0.00 Mil. Diamyd Medical AB's Total Stockholders Equity for the quarter that ended in May. 2025 was kr324.67 Mil. Diamyd Medical AB's debt to equity for the quarter that ended in May. 2025 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Diamyd Medical AB's Debt-to-Equity or its related term are showing as below:

OSTO:DMYD B' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.15 Max: 0.21
Current: 0.09

During the past 13 years, the highest Debt-to-Equity Ratio of Diamyd Medical AB was 0.21. The lowest was 0.09. And the median was 0.15.

OSTO:DMYD B's Debt-to-Equity is ranked better than
60.76% of 1022 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSTO:DMYD B: 0.09

Diamyd Medical AB Debt-to-Equity Historical Data

The historical data trend for Diamyd Medical AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Debt-to-Equity Chart

Diamyd Medical AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Debt-to-Equity

Get a 7-Day Free Trial

0.09

0.21

Diamyd Medical AB Quarterly Data
	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25
Debt-to-Equity	Get a 7-Day Free Trial															-	0.21	-	-	-

Competitive Comparison of Diamyd Medical AB's Debt-to-Equity

For the Biotechnology subindustry, Diamyd Medical AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamyd Medical AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Diamyd Medical AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Diamyd Medical AB's Debt to Equity Ratio for the fiscal year that ended in Aug. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	30.672)	/	145.92
	=	0.21

Diamyd Medical AB's Debt to Equity Ratio for the quarter that ended in May. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	324.671
	=	0.00

Diamyd Medical AB (OSTO:DMYD B) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Diamyd Medical AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

DYMDF:USA

Address

Kungsgatan 29, Stockholm, SWE, SE-111 56

Website

https://www.diamyd.com

Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines